The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.
 
Xianjun Yu
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Andrea Tazbirkova
Research Funding - Antengene; Arcus Biosciences; BeiGene; Checkpoint Therapeutics; Janssen-Cilag; Novotech
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Lilly; MSD; Pierre Fabre; Roche
 
Jianwei Yang
No Relationships to Disclose
 
Jinbo Yue
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Yueyin Pan
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Yanru Qin
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose
 
Rongfeng Song
No Relationships to Disclose
 
Jian Ruan
No Relationships to Disclose
 
Aiping Zhou
Consulting or Advisory Role - BeiGene Beijing
 
Yiping Mou
No Relationships to Disclose
 
Zimin Liu
No Relationships to Disclose
 
Zhenyang Liu
No Relationships to Disclose
 
Yongchang Zhang
No Relationships to Disclose
 
Michelle Morris
No Relationships to Disclose
 
Morteza Aghmesheh
No Relationships to Disclose
 
Hui Zhou
No Relationships to Disclose